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Young triple negative breast cancer (TNBC) patients are at high risk for developing very
aggressive brain metastases associated with a poor prognosis and a high mortality rate.
Preclinical models that allow follow-up by magnetic resonance imaging (MRI) can contribute
to the development of new therapeutic approaches for brain metastasis. To date, preclinical
brain tumor research has almost exclusively relied on xenograft mouse models. Yet, rats
are an ideal model for imaging of brain metastasis as their larger brain offers better relative
spatial resolution compared to a mouse brain. For the development of a clinically relevant
rat model for TNBC brain metastasis, the MDA-MB-231br/eGFP cancer cell line can be
used. However, as a result of species-dependent extracranial features, the propensity of the
MDA-MB-231br/eGFP cancer cell line to metastasize exclusively to the brain needs to be
enhanced by in vivo selection. In this study, repeated sequential passages of metastatic
cancer cells obtained from brain metastases in nude rats were performed. Brain metastasis
formation was evaluated using preclinical MRI, while bone metastasis formation was
assessed using high-resolution computed tomography (CT) and 2-deoxy-2-[18F] fluoro-D-
glucose ([18F] FDG) positron emission tomography (PET) imaging. Our results demon-
strated that the metastatic tumor burden in the rat brain (number and volume) significantly
increased with increasing passage, while the metastatic tumor burden in the skeleton (i.e.,
number of metastasis-affected bones) significantly decreased with increasing passage.
However, bone metastasis development was not reduced to a negligible amount. Conse-
quently, despite in vivo selection, our rat model is not recommended for investigating brain
metastasis as a single disease. Our findings highlight the importance of well-reasoned
selection of both the preclinical model and the cancer cell line in order to obtain reliable and
reproducible scientific results.
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Introduction
Brain metastasis poses a severe problem in the treatment of young triple negative breast cancer
(TNBC) patients with metastatic disease [1]. TNBC is an aggressive and heterogeneous breast
cancer subtype which lacks the common therapeutic targets, making the clinical management
of this type of breast cancer particularly challenging. Around 25% of the TNBC patients will
develop highly aggressive brain metastasis and the median survival from diagnosis is about 7.3
months [2]. Although significant improvements have been made in treatment and early diag-
nosis, metastatic brain tumors still remain associated with a poor prognosis and a high mortal-
ity rate [3,4]. Brain metastases are routinely diagnosed with contrast enhanced (CE) magnetic
resonance imaging (MRI) as it provides excellent soft tissue contrast and spatial resolution
resulting in anatomical detail [5].
Preclinical models that allow follow-up with medical imaging techniques provide a non-
invasive method to decipher the mechanisms underlying the metastatic process and to
develop new therapeutic approaches [6]. Moreover, imaging of small laboratory animals
offers the unique opportunity to monitor the entire spectrum of the disease process [7]. For
instance, brain metastasis development in the rat brain can be monitored by repeated MRI
without the need of sacrificing the animals [8]. Selection of an appropriate preclinical
model is crucial and mainly depends on the scientific question being investigated [9]. For
brain metastasis research, such a model should reflect the clinical observations and summa-
rize the metastatic process in its dynamic environment [10]. To date, preclinical TNBC
brain metastasis research has almost exclusively relied on xenograft mouse models, notwith-
standing rats are an ideal model for imaging of brain metastasis. Rats have a larger brain,
which offers better relative spatial resolution and clinical deterioration is expected to be less
extensive in function of total brain volume.
Our research group previously aimed to establish a clinically relevant rat model for TNBC
brain metastasis with the MDA-MB-231br (transduced with eGFP) cancer cell line originally
developed by Yoneda and colleagues [11,12]. Unfortunately, early formation of bone metasta-
ses was clinically observed and evidenced by 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) pos-
itron emission tomography (PET) and high-resolution computed tomography (CT) [12].
Consequently, this rat model was not suited for the study of brain metastasis as a single disease
and associated therapeutic strategies. In order to improve the tropism of the MDA-MB-231br/
eGFP cancer cell line to metastasize uniquely to the brain, in vivo selection in rats is required
[12].
In this study, we attempted to enhance the metastatic propensity of the MDA-MB-




The brain metastatic derivative of the TNBC cell line MDA-MB-231 transduced with eGFP
(MDA-MB-231br/eGFP) authenticated and free of mycoplasma was maintained as described
by Yoneda and colleagues [11].
MDA-MB-231br/eGFP cancer cells were grown in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal calf serum, 1% penicillin-streptomycin antibiotics, 0.0005% fun-
gizone, 1% pyruvate and 1 mg/ml geneticin at 37˚C and 10% CO2. The MDA-MB-231br/
eGFP cancer cell line was regularly tested for Mycoplasma by using the MycoAlert Plus Kit
(Lonza).
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Rat model for TNBC brain metastasis
This study protocol was approved by the Ghent University ethics committee for animal experi-
ments (ECD 14/18). All animals were kept and handled according to the European guidelines
and housed under environmentally controlled conditions (12 hours normal light/dark cycles,
20˚C– 24˚C and 40–70% relative humidity) with food and water ad libitum. Animals were
fasted overnight before [18F]FDG PET scans were performed.
Six groups of female nude rats (passage 1 (P1): n = 8, passage 2 (P2): n = 9, passage 3 (P3):
n = 8, passage 4 (P4): n = 5, passage 5 (P5): n = 10, passage 6 (P6): n = 8; 5-weeks old, Crl:
NIH-Foxn1rnu, Charles River) were intracardially injected with 100,000 MDA-MB-231br/
eGFP cancer cells using ultrasound guidance to target the left ventricle. For the intracardiac
injection, rats were anesthetized using 1.5–2% isoflurane gas mixed with oxygen administered
at a flow rate of 0.2 l/min and placed supine with all four limbs fixated on the heated stage.
Ultrasonographic gel was applied and an ultrasound probe (FUJIFILM VisualSonics, Vevo
2100, Toronto, Canada) was used to find the left ventricle of the heart. A syringe, secured into
a holder, containing a 400 μl suspension of cancer cells was injected slowly after visual confir-
mation of the needle (3/4-inch-long 27-gauge) in the left ventricle of the heart (Fig 1A). After
intracardiac injection, rats were examined by T2 weighted (T2w) MRI to monitor brain metas-
tasis development. Of note, our research group previously compared T2w MRI with CE T1
weighted (T1w) MRI for the detection of brain metastasis. These results indicated that T2w
MRI was the better option for detection of brain metastasis in our rat model for TNBC brain
metastasis using the MDA-MB-231br/eGFP cancer cell line [12].
Humane endpoints
Taking the humane endpoints into account, rats were immediately euthanized when clinical
or behavioral signs including paralysis, reduced activity, balance problems, absence of
Fig 1. Establishment of the MDA-MB-231br/eGFP subpopulations. a. Intracardiac injection of the MDA-MB-
231br/eGFP cancer cells using ultrasound guidance. b-d. Follow-up of metastasis development with multimodal
imaging. Preclinical 7 T MRI for assessment of brain metastases (b), [18F]FDG PET/CT for visualization of extracranial
metastases (c), and high-resolution CT for the detection of bone metastases (d). e. Isolation of the MDA-MB-231br/
eGFP cancer cells from the brain metastatic lesions followed by cell culture. This procedure was repeated five times.
https://doi.org/10.1371/journal.pone.0243156.g001
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grooming, hunched posture or recent weight loss (>20%) was observed. At the end of the
experiment or when the humane endpoints were reached, rats were euthanized by an intrave-
nous (IV) injection of pentobarbital (120 mg/kg).
Multimodal imaging
MRI for follow-up of brain metastasis formation. MRI was performed on a 7 T system
(PharmaScan 70/16, Bruker, Ettlingen, Germany) to visualize metastasis development in the
brain. The rats were anesthetized with 1.5–2% isoflurane and O2 and through a nose cone fixed
on the Bruker rat restrainer. A heating pad was placed beneath each rat to maintain body temper-
ature at 37˚C before it was placed inside the MRI. With the use of T2w MR images (SE RARE,
109 μm in-plane resolution, TR/TE 6346/37 ms) parenchymal metastases were visualized 3, 4, 5
and 6 weeks after intracardiac injection (i.e., post-injection (PI)) of the cancer cells [12] (Fig 1B).
[18F]FDG PET/CT for extracranial metastasis formation. For our experimental rat
model using the MDA-MB-231br/eGFP cancer cell line, the optimal imaging protocol for the
detection of extracranial metastases, especially bone metastases, has previously been deter-
mined as a [18F]FDG PET/CT scan acquired 4–5 weeks PI of the cancer cells [12].
Static whole-body [18F]FDG PET/CT (60 minutes acquisition, Triumph-II, Trifoil imag-
ing1, Northridge, USA) was assessed to evaluate potential metastasis development outside
the brain. Rats were anesthetized with 1.5–2% isoflurane and O2 for the duration of the PET/
CT acquisitions. Polyethylene tubing was placed in the lateral tail vein to allow IV injection of
37 MBq [18F]FDG. After tracer uptake of 60 minutes, the animals were imaged with their body
temperature maintained at 37˚C using a heated bed. PET data were reconstructed using a max-
imum likelihood expectation maximization (MLEM) algorithm with 50 iterations and a recon-
structed voxel size of 0.5 × 0.5 × 1.157 mm. A CT acquisition (Triumph-II, Trifoil imaging1,
Northridge, USA) was acquired directly after the PET scan, on the same imaging device, for
anatomical correlation (Fig 1C).
High-resolution CT for visualization of bone metastasis. For the detection of possible
bone metastases, full-body spiral high-resolution CT acquisitions (7 minutes acquisition,
X-CUBE, MOLECUBES NV, Ghent, Belgium) with 460 μA tube current and 50 kVp tube volt-
age were performed 4–5 weeks PI. The full body spiral scans were reconstructed using an itera-
tive algorithm (ISRA) with a voxel size of 200 μm (Fig 1D).
Establishment of the MDA-MB-231br subpopulations
To establish the MDA-MB-231br/eGFP subpopulations, the MDA-MB-231br/eGFP cancer
cells from the brain metastatic lesions (preferably from the rat with the lowest number of
metastasis-affected bones) were isolated, grown in culture (MDA-MB-231br/eGFP P1), and
again inoculated into the left ventricle of the heart of female nude rats. This procedure was
repeated five times (Table 1, Fig 1).
Table 1. Establishment of the MDA-MB-231br/eGFP subpopulations.
Passage Inoculated cancer cell line Isolated cancer cell line n =
1 MDA-MB-231br/eGFP MDA-MB-231br/eGFP P1 8
2 MDA-MB-231br/eGFP P1 MDA-MB-231br/eGFP P2 9
3 MDA-MB-231br/eGFP P2 MDA-MB-231br/eGFP P3 8
4 MDA-MB-231br/eGFP P3 MDA-MB-231br/eGFP P4 5
5 MDA-MB-231br/eGFP P4 MDA-MB-231br/eGFP P5 10
6 MDA-MB-231br/eGFP P5 MDA-MB-231br/eGFP P6 8
https://doi.org/10.1371/journal.pone.0243156.t001
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The brain metastatic lesions were dissociated to a single-cell suspension by enzymatic diges-
tion of the extracellular adhesion proteins and matrix proteins. The tissue was cut into small
pieces with a scalpel, then digested enzymatically and further dissociated into a single-cell sus-
pension with the brain tumor dissociation kit with trypsin (Miltenyi Biotec, Leiden, The Neth-
erlands) and the corresponding gentleMACS dissociator programs (Miltenyi Biotec, Leiden,
The Netherlands) according to the manufacturer’s instructions.
Image analysis
Volume and number of brain metastases were assessed on T2w MR images acquired 3 and 4
weeks after intracardiac injection of the cancer cells, when all rats were still alive [12]. Brain
metastases’ volumes were measured by manually outlining hyperintense regions on individual
slices of T2w MR images using OsiriX software (OsiriX v.5.8.1). The obtained tumor areas
were then multiplied by the slice thickness (0.6 mm) to calculate the volume of each brain
metastasis.
Bone metastasis development was assessed on high-resolution CT images acquired 4–5
weeks after intracardiac injection through counting the number of metastasis-affected bones.
Statistical analysis
For the number of brain metastases and the volume (total and average) of brain metastases,
linear mixed models were fitted with a random intercept for ‘animal ID’ to account for the
repeated measurements within animals. Passage (6 categories, with the sixth passage as refer-
ence), timepoint (week 3 and week 4), and their two-way interaction were included as fixed
effects. Estimated marginal means were computed for each combination of passage and time-
point together with their corresponding 95% Wald confidence intervals (CIs). These results
were visualized in a mean profile plot. Error bars represent the 95% CIs around the estimated
arithmetic means. To derive robust 95% CIs of the estimated mean differences (compared to
the sixth passage at a certain timepoint), we took 2500 samples using the Wild bootstrap
method and requested Bias Corrected and accelerated (BCa) CIs. In addition, linear mixed
models were fitted where passage was considered as a continuous covariate and the corre-
sponding estimated regression lines were plotted on top of the mean profile plot.
For the number of metastasis-affected bones two negative binomial models were fitted,
once with passage as a categorical fixed effect (with the sixth passage as reference) and once
with passage as continuous covariate. The predicted mean number of metastasis-affected
bones and corresponding 95% CIs are plotted according to the passage number.
No correction for multiple testing was performed, as Bonferroni correction was considered
too strict and conservative. However, when applying Bonferroni correction, p-values should
be compared to a significance level of 0.0029 as 17 comparisons were made for each ‘brain’
outcome.
All models were fitted with SPSS version 25. Mean profile plots were made with R (R ver-
sion 3.6.1).
Results
Analysis of brain metastases
T2w images were used to evaluate the tumor burden (i.e., total and average volume, and num-
ber of metastatic lesions) in the rat brain (Fig 2). The results of brain metastases analysis are
visualized for each passage at week 3 and week 4 after intracardiac injection of the cancer cells
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(Figs 3–5). Statistical analysis was performed on data acquired at week 3 and week 4 PI, when
all animals were still alive.
Number of brain metastases. Pairwise comparison of number of brain metastases at week 3
PI with the sixth passage as reference. The estimated mean number of brain metastases was sig-
nificantly lower for passage 1 and 2 compared to passage 6 (estimated mean difference =
-32.25, BCa 95% CI goes from -42.43 to -23.65, p< 0.001, and estimated mean difference =
-52.04, BCa 95% CI goes from -58.63 to -46.72, p< 0.001, respectively). No other significant
differences in estimated mean number of brain metastases were observed compared to passage
6 (Table 2, Fig 3A).
Pairwise comparison of number of brain metastases at week 4 PI with the sixth passage as ref-
erence. The estimated mean number of brain metastases was significantly lower for passage 2
compared to passage 6 (estimated mean difference = -48.3, BCa 95% CI goes from—62.94 to—
Fig 3. Graphical illustration of the estimated mean number of brain metastases. a. Estimated mean number of brain metastases at week 3
and week 4 after intracardiac injection of the cancer cells for each passage. b. Evolution of the estimated mean number of brain metastases
per passage at week 3 and 4 after intracardiac injection of the cancer cells.
https://doi.org/10.1371/journal.pone.0243156.g003
Fig 2. MR imaging of brain metastasis development per passage. a–f. In vivo serial T2w MRI scans showing an
increase of brain metastasis development per passage. T2w MR images from a representative case for P1 (a), P2 (b), P3
(c), P4 (d), P5 (e), P6 (f).
https://doi.org/10.1371/journal.pone.0243156.g002
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32.13, p< 0.001). In contrast, the estimated mean number of brain metastases was signifi-
cantly higher for passage 3 compared to passage 6 (estimated mean difference = +33.38, BCa
95% CI goes from + 22.33 to + 46.55, p< 0.001). We were unable to observe any other signifi-
cant differences in estimated mean number of brain metastases at week 4 PI between passage
1, 4 or 5 compared to passage 6 (Table 3, Fig 3).
Comparison of the slopes (i.e., estimated mean difference of number of brain metastases
between week 3 and week 4 PI) with the slope of the sixth passage as reference. There was a
Fig 4. Graphical illustration of the estimated mean total volume of brain metastases. a. Estimated mean total volume of brain metastases
at week 3 and week 4 after intracardiac injection of the cancer cells for each passage. b. Evolution of the estimated mean total volume of
brain metastases per passage at week 3 and 4 after intracardiac injection of the cancer cells.
https://doi.org/10.1371/journal.pone.0243156.g004
Fig 5. Graphical illustration of the estimated mean average volume of brain metastases. a. Estimated mean average volume of brain
metastases at week 3 and week 4 after intracardiac injection of the cancer cells for each passage. b. Evolution of the estimated mean average
volume of brain metastases per passage at week 3 and 4 after intracardiac injection of the cancer cells.
https://doi.org/10.1371/journal.pone.0243156.g005
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significant difference between the slope of passage 1 compared to the slope of passage 6 with
the slope of passage 1 being 43.25 counts larger compared to the slope of passage 6 (i.e., steeper
slope for passage 1) (BCa 95% CI for difference in slopes goes from -67.09 to -20.77 p = 0.040).
In addition, comparison between the slopes of passage 3 and 6 showed a significant difference,
where the slope of passage 3 is 30.5 counts larger compared to the slope of passage 6 (BCa 95%
CI for difference in slopes goes from -41.50 to -21.72, p = 0.002). We could not observe any
other significant difference of the slopes compared to passage 6 (Fig 3A).
Evolution per passage. At week 3 PI, the estimated mean number of brain metastases for
passage 1 was 41.18 (95% CI goes from 19.32 to 63.04) and significantly increases with 9.56 per
passage (95% CI goes from 2.39 to 16.73, p = 0.01). In contrast, we were unable to find any sig-
nificant association between estimated mean number of brain metastases and passage number
at week 4 PI (Fig 3B).
Total volume of brain metastases. Pairwise comparison of total volume of brain metasta-
ses at week 3 PI with the sixth passage as reference. The estimated mean total volume of brain
metastases was significantly lower for passage 1 and 2 compared to passage 6 (estimated mean
difference for passage 1 = -53.227, BCa 95% CI goes from -69.434 to -42.738, p< 0.001, and
estimated mean difference for passage 2 = -54.663, BCa 95% CI goes from -71.283 to -43.829,
p< 0.001, respectively). For passage 3, 4 and 5, we were unable to observe any significant dif-
ference in estimated mean total volume of brain metastases compared to passage 6 (Table 4,
Fig 4A).
Pairwise comparison of total volume of brain metastases at week 4 PI with the sixth passage
as reference. The results of the estimated mean total volume of brain metastases at week 4 PI
were similar to the results obtained at week 3 PI. The estimated mean total volume of brain
metastases was significantly lower for passage 1 and 2 compared to passage 6 (estimated mean
difference for passage 1 = -160.5, BCa 95% CI goes from -206.6 to -107.26, p< 0.001, and esti-
mated mean difference for passage 2 = -163.4, BCa 95% CI goes from -207.5 to -110.8,
p< 0.001, respectively). For passage 3, 4 and 5, we could not observe any significant difference
in estimated mean total volume of brain metastases compared to passage 6 (Table 5, Fig 4A).
Table 3. Pairwise comparison of the estimated mean number of brain metastases at week 4 PI with the sixth passage as reference.
Passage Estimate Sig. (2-tailed) Bca 95% CI
Lower Bound Upper Bound
1 11.000 0.461 -14.152 37.756
2 -48.250 < 0.001 -62.939 -32.131
3 33.375 < 0.001 -22.334 46.555
4 3.150 0.641 -7.740 16.259
5 12.350 0.299 -3.984 31.265
6 0
https://doi.org/10.1371/journal.pone.0243156.t003
Table 2. Pairwise comparison of estimated mean number of brain metastases at week 3 PI with the sixth passage as reference.
Passage Estimate Sig. (2-tailed) Bca 95% CI
Lower Bound Upper Bound
1 -32.250 < 0.001 -42.432 -23.652
2 -52.042 < 0.001 -58.633 -46.718
3 2.875 0.462 -2.507 6.710
4 7.625 0.051 -1.831 12.220
5 2.725 0.813 -8.623 12.725
6 0
https://doi.org/10.1371/journal.pone.0243156.t002
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Comparison of the slopes (i.e., estimated mean difference of total volume of brain metastases
between week 3 and week 4 PI) with the slope of the sixth passage as reference. Evaluation of the
slopes (as illustrated in Fig 4A) showed a significant difference between passage 1 and passage
6 where the slope of passage 1 is 107.2 counts lower compared to the slope of passage 6 (i.e.,
steeper slope for passage 6) (BCa 95% CI for difference in slopes goes from 67.9 to 137.1,
p< 0.001). In addition, we found a significant difference between the slopes of passage 2 and
passage 6 where the slope of passage 2 is 108.7 counts lower compared to the slope of passage 6
(BCa 95% CI for difference in slopes goes from 69.9 to 138.4, p< 0.001). For passage 3, 4 and
5, we were unable to observe any significant difference between slopes compared to passage 6
(Fig 4A).
Evolution per passage. At week 3 PI, the estimated mean total volume of brain metastases
was 5.33 mm3 for passage 1 (95% CI goes from -23.87 to 34.54) and significantly increased
with 13.23 mm3 per passage (95% CI goes from 3.65 to 22.81, p = 0.007). At week 4 PI, a signif-
icant increase of 37.86 mm3 per passage was observed (95% CI goes from 28.28 to 47.45,
p< 0.001) with 47.20 mm3 being the estimated mean total volume of brain metastases for pas-
sage 1 (95% CI goes from -17.99 to 76.41) (Fig 4B).
Average volume of brain metastases. Pairwise comparison of average volume of brain
metastases at week 3 PI with the sixth passage as reference. The estimated mean average volume
of brain metastases was significantly lower for passage 1 and 2 compared to passage 6 (esti-
mated mean difference = -0.639, BCa 95% CI goes from -0.979 to -0.299, p< 0.001; estimated
mean difference = -0.591, BCa 95% CI goes from -0.922 to -0.261, p = 0.001, respectively). For
passage 3, 4 and 5, we were unable to observe any significant difference in estimated mean
average volume of brain metastases compared to passage 6 (Table 6, Fig 5A).
Pairwise comparison of average volume of brain metastases at week 4 PI with the sixth pas-
sage as reference. The estimated mean average volume of brain metastases was significantly
lower for passage 1, 2 and 3 compared to passage 6 (estimated mean difference between pas-
sage 1 and 6 = -1.7, BCa 95% CI goes from -2.0 to -1.3, p< 0.001; estimated mean difference
Table 5. Pairwise comparison of estimated mean total volume of brain metastases at week 4 PI with the sixth passage as reference.
Passage Estimate Sig. (2-tailed) Bca 95% CI
Lower Bound Upper Bound
1 -160.506 < 0.001 -206.626 -107.264
2 -163.376 < 0.001 -207.521 -110.805
3 -20.712 0.541 -77.043 44.554
4 16.518 0.735 -54.114 97.585
5 -0.798 0.979 -53.327 58.510
6 0
https://doi.org/10.1371/journal.pone.0243156.t005
Table 4. Pairwise comparison of estimated mean total volume of brain metastases at week 3 PI with the sixth passage as reference.
Passage Estimate Sig. (2-tailed) Bca 95% CI
Lower Bound Upper Bound
1 -53.227 < 0.001 -69.434 -42.738
2 -54.663 < 0.001 -71.282 -43.829
3 -21.251 0.171 -39.588 -9.447
4 12.782 0.359 -4.292 23.783
5 0.829 0.953 -17.651 13.298
6 0
https://doi.org/10.1371/journal.pone.0243156.t004
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between passage 2 and 6 = -1.4, BCa 95% CI goes from -1.7 to -1.0, p< 0.001; and estimated
mean difference between passage 3 and 6 = -0.7, BCa 95% CI goes from -1.1 to -0.3, p = 0.003).
For passage 4 and 5, we were unable to observe any significant difference in estimated mean
average volume of brain metastases compared to passage 6 (Table 7, Fig 5A).
Comparison of the slopes (i.e., estimated mean difference of average volume of brain metasta-
ses between week 3 and week 4 PI) with the slope of the sixth passage as reference. Comparison
of the slopes among passages revealed a significant difference between passage 1 and 6, with
the mean difference being 1.02 counts lower for passage 1 compared to passage 6 (BCa 95% CI
for difference in slopes goes from 0.70 to 1.30, p< 0.001). The slope of passage 2 was also sig-
nificantly different compared to the slope of passage 6, with the slope of passage 2 being 0.77
counts lower compared to passage 6 (BCa 95% CI for difference in slopes goes from 0.45 to
1.06, p = 0.001). For passage 3, 4 and 5, we were unable to observe any significant difference
between the slopes compared to passage 6.
Evolution per passage. At week 3 PI, the estimated mean average volume of brain metastases
for passage 1 was 0.13 mm3 (95% CI goes from -0.05 to 0.31), and significantly increased with
0.14 mm3 per passage (95% CI goes from 0.01218 to 0.20, p< 0.001). At week 4 PI, the esti-
mated mean average volume of brain metastases for passage 1 was 0.39 mm3 (95% CI goes
from 0.30 to 0.41, p< 0.001), and significantly increased with 0.35 mm3 per passage (95% CI
goes from 0.30 to 0.41, p< 0.001) (Fig 5B).
Number of metastasis-affected bones
We were unable to find any significant difference in estimated mean number of metastasis-
affected bones between passage 1, 2, 3, 4 or 5 compared to passage 6 (Table 8). However, the
estimated mean number of metastasis-affected bones decreased significantly with 16% per pas-
sage (95% CI goes from -0.2% to—29.3%, p = 0.048) (Fig 6).
Table 6. Pairwise comparison of estimated mean average volume of brain metastases at week 3 PI with the sixth passage as reference.
Passage Estimate Sig. (2-tailed) Bca 95% CI
Lower Bound Upper Bound
1 -0,639 < 0.001 -0.979 -0.299
2 -0,591 0.001 -0.922 -0.261
3 -0.303 0.079 -0.643 0.037
4 0.028 0.887 -0.360 0.415
5 -0,073 0.656 -0.395 0.250
6 0
https://doi.org/10.1371/journal.pone.0243156.t006
Table 7. Pairwise comparison of estimated mean average volume of brain metastases at week 4 PI with the sixth passage as reference.
Passage Estimate Sig. (2-tailed) Bca 95% CI
Lower Bound Upper Bound
1 -1.662 < 0.001 -1.962 -1.318
2 -1.366 < 0.001 -1.679 -1.011
3 -0.712 0.003 -1.084 -0.326
4 -0.134 0.682 -0.628 0.404
5 -0.167 0.562 -0.582 0.251
6 0
https://doi.org/10.1371/journal.pone.0243156.t007
PLOS ONE In vivo selection of the MDA-MB-231br/eGFP cancer cell line to obtain a rat model for brain metastasis
PLOS ONE | https://doi.org/10.1371/journal.pone.0243156 December 2, 2020 10 / 15
Discussion
To date, the pathophysiology of brain metastasis and preclinical validation of therapeutic
approaches has almost exclusively relied on xenograft mouse models. Until recently, intracar-
diac injection of mice with brain-seeking cancer cells derived from MDA-MB-231 (TNBC)
and BT474 (HER2+) breast cancer cell lines are the most frequently used models for breast
cancer brain metastasis as they produce brain metastases at high frequencies [13,14]. Neverthe-
less, rats are an excellent model for brain metastasis imaging as their larger brain offers better
relative spatial resolution. Therefore, our research group previously aimed at developing a clin-
ically relevant rat model for TNBC brain metastasis with the MDA-MB-231br/eGFP cancer
cell line [11,12]. Unfortunately, early bone metastasis was clinically observed and evidenced by
PET/CT. The bones lesions caused severe clinical symptoms leading to early euthanasia of sev-
eral rats. Consequently, this rat model was not suited for investigating brain metastasis as a
Table 8. Pairwise comparison of estimated mean number of metastasis-affected bones with the sixth passage as
reference.
Passage Exp(B) Sig. (2-tailed) Bca 95% CI for Exp(B)
Lower Bound Upper Bound
1 2.631 0.063 0.948 7.301
2 1.860 0.223 0.686 5.041
3 2.631 0.063 0.948 7.301
4 1.083 0.895 0.332 3.528
5 1.489 0.424 0.560 3.957
6 1
https://doi.org/10.1371/journal.pone.0243156.t008
Fig 6. Graphical illustration of the evolution of the estimated mean number of metastasis-affected bones per
passage.
https://doi.org/10.1371/journal.pone.0243156.g006
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single disease and testing associated therapeutic strategies [12]. In order to reduce the amount
of metastatic bone lesions to a negligible amount, the tropism of the MDA-MB-231br/eGFP
cancer cell line to metastasize uniquely to the brain needs to be enhanced.
For this purpose, in vivo selection in rats has been performed in the present study. Brain
metastasis development was assessed with preclinical MRI because of its noninvasive nature,
high spatial resolution (up to 50 μm at 7 T) and high signal-to-noise ratio [15]. MRI allows lon-
gitudinal follow-up and is an excellent tool for the study of tumor growth. In this study, brain
metastasis development (i.e., total and average volume, and number of metastatic lesions) was
evaluated on T2w images acquired 3 and 4 weeks PI based on the imaging protocol previously
described by our research group (Table 9 gives an overview of the p-values) [12]. At week 3 PI,
the estimated mean number of brain metastases was significantly lower for passage 1 and 2
compared to passage 6. Moreover, we observed that the estimated mean number of brain metas-
tases significantly increased with 9.56 per passage. At week 4 PI, the estimated mean number of
brain metastases was significantly lower for passage 2 compared to passage 6, but the estimated
mean number of brain metastases was significantly higher for passage 3 compared to passage 6.
In addition, we were unable to find a significant association between estimated mean number
of brain metastases and passage number. This inconsistent observation for estimated mean
number of brain metastases at week 4 PI might be the result of the complex relation between
number and volume of brain metastases. Percy et al. reported that animals with fewer metasta-
ses more often developed larger metastases after inoculation with the MDA-MB-231br cancer
cell line [16]. Hence, estimated mean number of brain metastases alone is not an ideal represen-
tation for tumor load in the brain. In addition, we evaluated the total and average volume of the
brain metastases. The estimated mean total volume of brain metastases was found to be signifi-
cantly lower for passage 1 and 2 compared to passage 6 at both week 3 and week 4 PI. Moreover,
we observed a significant association between estimated mean total volume of brain metastases
and number of passage where the estimated mean total volume of brain metastases increased
with 13.23 mm3 per passage at week 3 PI and with 37.86 mm3 per passage at week 4 PI. A simi-
lar result was observed for the estimated mean average volume of brain metastases. At week 3
PI, the estimated mean average volume of brain metastases was significantly lower for passage 1
and 2 compared to passage 6. Along with passage 1 and 2, the estimated mean average volume
of brain metastases for passage 3 was also significantly lower compared to passage 6 at week 4
PI. Moreover, we observed a significant indication for an increasing estimated mean average
volume of brain metastases with 0.14 mm3 per passage at week 3 PI and 0.35 mm3 per passage
at week 4 PI. These observations indicate that the metastatic tumor load in the brain signifi-
cantly increased with increasing passage. For the evaluation of tumor burden in the skeleton of
the rat, the number of metastasis-affected bones was assessed on high-resolution CT images
Table 9. Overview of p-values with the sixth passage as reference.
Passage Number of brain metastases Total volume of brain metastases Average volume of brain metastases Number of affected bones
Week 3 Week 4 Week 3 Week 4 Week 3 Week 4 Week 4
1 <0.001 0.461 <0.001 <0.001 <0.001 <0.001
2 <0.001 <0.001 <0.001 <0.001 0.001 <0.001
3 0.461 <0.001 0.171 0.541 0.079 0.003
4 0.051 0.641 0.359 0.735 0.887 0.682
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acquired 4–5 weeks PI for each passage. Statistical analysis revealed that the estimated mean
number of metastasis-affected bones decreased significantly with 16% per passage (Table 8), as
we had expected. Although the estimated mean number of metastasis-affected bones continued
to decrease per passage, it was never reduced to an amount that was clinically negligible as pre-
viously reported for mice by our research group. We observed and evidenced one metastasis-
affected bone (the skull) in two out of five mice [12].
Our findings are different to those obtained by Yoneda and colleagues [11]. They developed a
brain-seeking clone of the MDA-MB-231 cell line (MDA-MB-231br) by performing repeated
sequential passages of metastatic cancer cells obtained from brain metastases in nude mice. The
resulting MDA-MB-231br cancer cell line has been described to exclusively disseminate to the
mouse brain as no bone metastatic lesions were confirmed with radiographic analysis [11]. Radiog-
raphy is generally not used as a screening method for bone metastatic lesions because of its poor
sensitivity. Several studies have revealed that bone destruction of 50% or more is required for
appropriate radiographic detection of bone lesions [17–21]. We assessed high-resolution CT for the
detection of the metastatic bone lesions, which is more sensitive compared to radiography [12,20].
CT exhibits superior anatomical detail and distinguishes between different densities, even allowing
detection of metastases within the bone marrow before bone destruction has appeared [20].
Of note, these xenograft animal models established by intracardiac injection of brain-seek-
ing cancer cells do not completely represent the heterogeneity of breast cancer and their
metastasis [13,14]. In order to provide a better representation of the original tumors of the
patients, patient-derived xenograft (PDX) models can be used. However, PDX models for
brain metastasis may also develop ‘undesired’ metastasis to other organs resulting in clinical
symptoms and hampering long-term follow-up [13,14,22].
In conclusion, we report that the metastatic tumor burden in the rat brain significantly
increased with increasing passage, while the metastatic tumor burden in the skeleton signifi-
cantly decreased with increasing passage. Unfortunately, we were unable to reduce bone
metastasis formation to a negligible amount after in vivo selection. Therefore, this rat model
using the MDA-MB-231br/eGFP is not ideal for investigating brain metastasis as a single dis-
ease and testing associated therapeutic strategies. Our observations highlight the importance
of well-reasoned selection of the preclinical model and the cancer cell line in order to obtain
reliable and reproducible scientific results.
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14. Contreras-Zárate MJ, Ormond DR, Gillen AE, Hanna C, Day NL, Serkova NJ, et al. Development of
Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases. Front Oncol. 2017; 7:252.
https://doi.org/10.3389/fonc.2017.00252 PMID: 29164052
15. Murrell DH, Foster PJ, Chambers AF. Brain metastases from breast cancer: lessons from experimental
magnetic resonance imaging studies and clinical implications. J Mol Med. 2014; 92(1):5–12. https://doi.
org/10.1007/s00109-013-1108-z PMID: 24306136
16. Perera M, Ribot EJ, Percy DB, McFadden C, Simedrea C, Palmieri D, et al. In Vivo Magnetic Reso-
nance Imaging for Investigating the Development and Distribution of Experimental Brain Metastases
due to Breast Cancer. Transl Oncol. 2012; 5(3):217–25. https://doi.org/10.1593/tlo.12109 PMID:
22741041
17. O’Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: An update. World J Radiol. 2015 Aug
28; 7(8):202–11. https://doi.org/10.4329/wjr.v7.i8.202 PMID: 26339464
18. Cuccurullo V, Cascini GL, Tamburrini O, Mansi AR and L. Bone Metastases Radiopharmaceuticals: An
Overview. Vol. 6, Current Radiopharmaceuticals. 2013. p. 41–7. https://doi.org/10.2174/
1874471011306010007 PMID: 23470032
19. Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis of bone metastases. QJ Nucl Med.
2001; 45(1):53–64.
20. Choi J, Raghavan M. Diagnostic Imaging and Image-Guided Therapy of Skeletal Metastases. Cancer
Control. 2012 Apr 1; 19(2):102–12. https://doi.org/10.1177/107327481201900204 PMID: 22487972
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